Phase Holographic Imaging

20/04/2025

from your PHI team 🐣

05/11/2024

We’re thrilled to welcome Anders Månsson as PHI’s new CEO! 🚀 Anders has kickstarted his first week: “I am very happy to have joined PHI, and I am energized by the team’s dedication to the innovative edge of our HoloMonitor® technology. Together, we will drive new standards in cell monitoring, and support advancements in cell-based therapies, for the benefit of patients around the world. I look forward to connecting with our partners, collaborators, and the PHI community.”

22/08/2024

🎙️

16/08/2024

🎉 Great news to wake up to! 📈 PHI is now dual-listed and can be traded on the U.S. OTCQB Market!

🇺🇸 Ticker: OTCQB:PHIXF

We are thrilled that PHI shares can now also be traded on the OTCQB Market at OTC Markets Group, alongside our existing listing on Stockholm's Spotlight Stock Market. This strategic move enhances our presence and investor accessibility in the U.S. market.

CEO Patrik Eschricht shares, "The dual-listing on the OTCQB Market boosts our visibility in the U.S., aligning with our mission to advance regenerative medicine. It's a strategic step to enhance liquidity and shareholder value, fueling PHI's continued growth."

🔗 Read more: https://phiab.com/pressrelease/phi-enters-the-us-capital-market-shares-now-also-traded-on-otcqb/

PHI is thrilled to announce its official approval for also listing on the OTCQB Venture Market in the U.S., with trading commencing Thursday, August 15th. (OTCQB:PHIXF).

29/04/2024

"We stand right at the forefront of the revolution in , and we are incredibly proud to contribute to cure previously incurable diseases," comments our CEO Patrik Eschricht in the 📰 Swedish business magazine Affärsvärlden.

Read the whole article (🇸🇪 in Swedish):
🔗

Cancer, diabetes och Parkinson – många obotliga sjukdomar kommer snart kunna botas tack vare modern, regenerativ medicin.

04/10/2023

Fluorescence training in full swing:
Cell-Bio Taiwan visits PHI! 🌟🇹🇼🌍

Cindy and Chris from our distributor Cell-Bio made the journey all the way from Taiwan to our headquarters in Lund for some intensive hands-on training with our latest 🔬 We've exchanged not only knowledge but some delightful international culinary treats. 🍰🍮

Nothing beats the excitement of global collaboration to transform how scientists study living cells!

27/09/2023

🌟 New Review Alert! 🌟

Happy to share the latest SelectScience® review of our by Nattawan Suwannakul, postdoc University.

🔬 Application: Cell morphology & functional tests in human & mouse cell lines.

Nattawan's Review:
"We appreciate to use the Holomonitor to provide the powerful results with multiple assays in cell biological analysis. The images/video and data can be use for research with high impact. We are truly delightful the quick responses by the PHI company regarding the introduction, troubleshooting, maintenances, and advice with kind services. We hope to get to learn new technology from you and apply for the research."

Thank you, Nattawan!

26/07/2023

📰 New technology article by PHI in BioPhotonics latest issue!

Read it here ➡️ https://phiab.com/blog/biophotonics-issue-july-august-2023-quantitative-phase-imaging-advances-regenerative-medicine/

14/07/2023

in the lab 🏖️
🐙What are your up to?

07/07/2023

PHI charts a bold course to impact regenerative medicine - Patrik Eschricht, CEO, comments on the latest report and looks ahead.

04/07/2023

🎇Happy Independence Day to our US colleagues, partners, customers and their cells. We wish you all a great day celebrating.